Jagsonpal Pharmaceuticals Limited (BOM:507789)
India · Delayed Price · Currency is INR 174.25
-4.90 (-2.74%)
At close: Feb 13, 2026
Jagsonpal Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 2,816 | 2,687 | 2,087 | 2,367 | 2,176 | 1,879 |
Revenue | 2,816 | 2,687 | 2,087 | 2,367 | 2,176 | 1,879 |
Revenue Growth (YoY) | 11.02% | 28.76% | -11.83% | 8.79% | 15.77% | 18.53% |
Cost of Revenue | 1,029 | 969.61 | 805.48 | 926.98 | 896.91 | 812.37 |
Gross Profit | 1,787 | 1,718 | 1,282 | 1,440 | 1,279 | 1,067 |
Selling, General & Admin | 853.35 | 820.97 | 635.52 | 729.76 | 703.71 | 658.72 |
Other Operating Expenses | 333.71 | 317.83 | 272.55 | 269.53 | 319.67 | 209.64 |
Operating Expenses | 1,325 | 1,288 | 1,065 | 1,101 | 1,039 | 879.22 |
Operating Income | 461.99 | 429.4 | 216.07 | 338.85 | 239.87 | 187.86 |
Interest Expense | -9.35 | -8.58 | -7.77 | -2.78 | -2.61 | -4.28 |
Interest & Investment Income | 76.45 | 76.45 | 85.92 | 34.28 | 15.46 | 29.92 |
Other Non Operating Income (Expenses) | 38.52 | 4.45 | 4.47 | 3.11 | 1.5 | 5.21 |
EBT Excluding Unusual Items | 567.61 | 501.72 | 298.69 | 373.46 | 254.22 | 218.72 |
Merger & Restructuring Charges | -34.97 | -34.97 | - | - | - | - |
Impairment of Goodwill | - | - | - | -0.3 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | 5.92 | 11.35 | - |
Gain (Loss) on Sale of Assets | - | - | - | 3.59 | 0.85 | - |
Asset Writedown | -1.75 | -1.75 | - | -27.79 | - | - |
Other Unusual Items | 13.81 | 233.59 | - | -6.8 | - | - |
Pretax Income | 544.7 | 698.59 | 298.69 | 348.08 | 266.42 | 218.72 |
Income Tax Expense | 135.67 | 144.98 | 74.06 | 80.87 | 77.87 | 48.14 |
Net Income | 409.03 | 553.61 | 224.63 | 267.21 | 188.55 | 170.58 |
Net Income to Common | 409.03 | 553.61 | 224.63 | 267.21 | 188.55 | 170.58 |
Net Income Growth | -21.83% | 146.45% | -15.93% | 41.72% | 10.53% | 116.73% |
Shares Outstanding (Basic) | 67 | 67 | 66 | 65 | 65 | 65 |
Shares Outstanding (Diluted) | 67 | 67 | 66 | 65 | 65 | 65 |
Shares Change (YoY) | 0.36% | 1.56% | 1.23% | - | - | - |
EPS (Basic) | 6.12 | 8.26 | 3.40 | 4.08 | 2.88 | 2.60 |
EPS (Diluted) | 6.07 | 8.22 | 3.39 | 4.08 | 2.88 | 2.60 |
EPS Growth | -22.14% | 142.48% | -16.91% | 41.72% | 10.55% | 117.00% |
Free Cash Flow | - | 549.52 | 349.18 | 463.37 | 58.65 | 277.53 |
Free Cash Flow Per Share | - | 8.16 | 5.27 | 7.08 | 0.90 | 4.24 |
Dividend Per Share | - | 2.500 | 2.000 | 2.000 | 1.600 | 0.400 |
Dividend Growth | - | 25.00% | - | 25.00% | 300.00% | 100.00% |
Gross Margin | 63.47% | 63.92% | 61.41% | 60.84% | 58.78% | 56.78% |
Operating Margin | 16.41% | 15.98% | 10.35% | 14.31% | 11.02% | 10.00% |
Profit Margin | 14.53% | 20.60% | 10.76% | 11.29% | 8.67% | 9.08% |
Free Cash Flow Margin | - | 20.45% | 16.73% | 19.57% | 2.70% | 14.77% |
EBITDA | 575.29 | 496.31 | 221.13 | 347.11 | 255.13 | 198.72 |
EBITDA Margin | 20.43% | 18.47% | 10.60% | 14.66% | 11.73% | 10.57% |
D&A For EBITDA | 113.3 | 66.91 | 5.06 | 8.26 | 15.26 | 10.86 |
EBIT | 461.99 | 429.4 | 216.07 | 338.85 | 239.87 | 187.86 |
EBIT Margin | 16.41% | 15.98% | 10.35% | 14.31% | 11.02% | 10.00% |
Effective Tax Rate | 24.91% | 20.75% | 24.80% | 23.23% | 29.23% | 22.01% |
Revenue as Reported | 2,932 | 2,769 | 2,180 | 2,424 | 2,210 | 1,923 |
Advertising Expenses | - | 175.42 | 138.58 | 147.3 | 102.19 | 96.22 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.